文献速递慢性静脉疾病

大隐静脉齐口激光消融至隐股交界处的可行性与安全性

Feasibility and safety of flush endovenous laser ablation of the great saphenous vein up to the saphenofemoral junction.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-04-10

本研究为单中心回顾性分析,纳入2017年9月至2018年10月连续135例大隐静脉齐口腔内激光消融(fEVLA)手术,使用1470nm环形发射光纤。结果显示94.1%病例技术可行,EHIT 2-3级发生率各0.8%,齐口闭塞率在术后第1天、第10天和第6周分别为94.5%、95.3%和88.2%,表明fEVLA可行且似乎安全。

要点

  • fEVLA技术可行率达94.1%,仅5.9%因导管尖端无法到位而改标准消融。
  • EHIT 2级和3级各发生0.8%,经利伐沙班抗凝2-3周后均消退无后遗症。
  • 齐口闭塞率第1天94.5%、第10天95.3%、第6周88.2%,无腹股沟局部并发症。

核心结论

  • 使用环形发射激光的fEVLA治疗大隐静脉可行且似乎安全。

研究设计与样本

  • 单中心回顾性分析前瞻性收集数据,纳入2017年9月至2018年10月连续135例fEVLA手术,共113例患者(86女,27男)。

主要发现

  • 127例(94.1%)fEVLA技术可行,8例(5.9%)无法放置导管尖端而改行标准消融。
  • 术后第10天发生EHIT 2级1例(0.8%)和EHIT 3级1例(0.8%),经利伐沙班抗凝2-3周后均消退无后遗症。
  • 发生浅静脉血栓1例(0.8%)和小腿静脉血栓1例(0.8%,位于剥脱术部位),无腹股沟局部并发症。
  • 齐口闭塞率第1天94.5%、第10天95.3%、第6周88.2%。
  • 多因素回归分析显示第1天齐口消融与年龄、BMI、CEAP分级、光纤类型、最大静脉直径或每厘米应用焦耳数无显著关联。

关键数值与推荐

  • 隐股交界处大隐静脉直径平均9.4±2.7 mm,最大16 mm。
  • CEAP临床分级:C2 78例(57.8%),C3 48例(35.6%),C4 8例(5.9%),C5 1例(0.7%)。
  • 126例(93.3%)同期行属支剥脱或泡沫硬化剂治疗。

临床怎么用

  • 对于大隐静脉直径达16 mm的病例,fEVLA可作为可行选项,但需注意导管尖端到位性。
  • 术后需监测EHIT,发生EHIT 2-3级时可用利伐沙班抗凝2-3周。

局限性

  • 单中心回顾性设计,样本量有限,缺乏对照组,随访仅至第6周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal ablation distance from the catheter tip to the common femoral vein during endovenous laser ablation (EVLA) of the great saphenous vein (GSV) is a matter of debate. In this study, we evaluated the feasibility and safety of flush ablation (fEVLA) of the GSV. METHODS: This single-center, retrospective analysis of prospectively collected data included all consecutive fEVLA interventions of the GSV between September 2017 and October 2018. Interventions were performed with a 1470-nm radially emitting fiber. Primary end points were technical feasibility of fEVLA and endovenous heat-induced thrombosis (EHIT) class 2 to class 4. Secondary end points were procedure-related complications; anatomic success at week 6; and flush occlusion at day 1, day 10, and week 6. RESULTS: A total of 135 consecutive intended fEVLA procedures were performed in 113 patients (86 female, 27 male). The average body mass index was 24.9 ± 4.3 kg/m2. The Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) clinical class for these patients was C2 in 78 (57.8%), C3 in 48 (35.6%), C4 in 8 (5.9%), and C5 in 1 (0.7%). The GSV diameter at the saphenofemoral junction was 9.4 ± 2.7 mm with a maximum of 16 mm. In 126 cases (93.3%), concomitant treatment of tributaries with phlebectomy or foam sclerotherapy was performed. In 127 cases (94.1%), fEVLA was technically feasible; in 8 cases (5.9%), appropriate catheter tip placement was not possible. In these cases, "standard" GSV ablation 10 to 20 mm distal to the saphenofemoral junction was performed. In the remaining 127 cases, one (0.8%) EHIT class 2 and one (0.8%) EHIT class 3 developed at day 10. After a 2- to 3-week course of anticoagulation with rivaroxaban, these EHIT cases resolved without sequelae. Furthermore, one (0.8%) superficial vein thrombosis and one (0.8%) calf vein thrombosis at the site of phlebectomy were observed. No local groin complication occurred. Flush occlusion was observed in 94.5%, 95.3%, and 88.2% of the cases at day 1, day 10, and week 6, respectively. Multivariate regression analysis revealed no significant association between flush ablation at day 1 and age, body mass index, CEAP class, fiber type, maximum vein diameter, or applied joules per centimeter. CONCLUSIONS: The results of this study suggest that fEVLA of the GSV using a radial emitting laser is feasible and seems to be safe.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Spinedi L, Stricker H, Keo HH, et al. Feasibility and safety of flush endovenous laser ablation of the great saphenous vein up to the saphenofemoral junction. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32284310. doi:10.1016/j.jvsv.2020.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。